RTOG 0920 A PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCER

Objective

The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone with radiation therapy and cetuximab cancer to find out which is better. In this study, patients will get either radiation therapy alone OR radiation therapy and cetuximab.

IRB Protocol Number

10-0095

Principal Investigator(s)

DAVID RABEN

Cancer Trials

• Head and Neck Cancers

Sponsor(s)

RTOG

Contact

ROBYN SWING at 720-848-0607
or ROBYN.SWING@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period (s) that can last up to 11 weeks. Patients will be followed for life. // Eligibility criteria include but are not limited to 18 years or older with head and nexk cancer.